Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
618
mi
from
Nashville, TN
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Research Site
8655
mi
from
Kogarah,
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Research Site
8655
mi
from
Kogarah,
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
976
mi
from
Winston-Salem, NC
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated:  12/7/2017
UPMC Presbyterian
974
mi
from
Pittsburgh, PA
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated: 12/7/2017
UPMC Presbyterian
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated:  12/7/2017
Hillman Cancer Center
975
mi
from
Pittsburgh, PA
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated: 12/7/2017
Hillman Cancer Center
975
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated:  12/7/2017
UPMC - Shadyside
974
mi
from
Pittsburgh, PA
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status: Enrolling
Updated: 12/7/2017
UPMC - Shadyside
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Pinnacle Oncology Hematology
840
mi
from
Scottsdale, AZ
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Pinnacle Oncology Hematology
840
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Yale University
1344
mi
from
New Haven, CT
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Harvard-Mass General Hospital
1443
mi
from
Boston, MA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Harvard-Mass General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Univ of Washington
1410
mi
from
Seattle, WA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Univ of Washington
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results
Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results
Status: Enrolling
Updated:  12/7/2017
Eleanor N. Dana Cancer Center
799
mi
from
Toledo, OH
Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results
Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results
Status: Enrolling
Updated: 12/7/2017
Eleanor N. Dana Cancer Center
799
mi
from
Toledo, OH
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Children's Hospital Boston
1442
mi
from
Boston, MA
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Children's Hospital Boston
1442
mi
from
Boston, MA
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
Status: Enrolling
Updated:  12/8/2017
UT MD Anderson Cancer Center
572
mi
from
Houston, TX
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
Status: Enrolling
Updated: 12/8/2017
UT MD Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated:  12/8/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated: 12/8/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Decatur Memorial Hospital
499
mi
from
Decatur, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Decatur Memorial Hospital
499
mi
from
Decatur, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Ingalls Memorial Hospital
601
mi
from
Harvey, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Ingalls Memorial Hospital
601
mi
from
Harvey, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Fort Wayne Medical Oncology and Hematology
718
mi
from
Fort Wayne, IN
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Fort Wayne Medical Oncology and Hematology
718
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
NorthShore University Health System
612
mi
from
Evanston, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
NorthShore University Health System
612
mi
from
Evanston, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Indiana University Medical Center
643
mi
from
Indianapolis, IN
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Indiana University Medical Center
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Virginia Mason
1382
mi
from
Seattle, WA
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Virginia Mason
1382
mi
from
Seattle, WA
Click here to add this to my saved trials
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/8/2017
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/8/2017
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Click here to add this to my saved trials
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy
Status: Enrolling
Updated:  12/8/2017
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy
Status: Enrolling
Updated: 12/8/2017
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Study for Using Radiosurgery on Limited Metastases of Breast Cancer
A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer
Status: Enrolling
Updated:  12/8/2017
Department of Radiation Oncology: University of Rochester
1121
mi
from
Rochester, NY
Study for Using Radiosurgery on Limited Metastases of Breast Cancer
A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer
Status: Enrolling
Updated: 12/8/2017
Department of Radiation Oncology: University of Rochester
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated:  12/10/2017
University of Michigan, School of Nursing
808
mi
from
Ann Arbor, MI
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated: 12/10/2017
University of Michigan, School of Nursing
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung
Status: Enrolling
Updated:  12/10/2017
Burzynski Clinic
565
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung
Status: Enrolling
Updated: 12/10/2017
Burzynski Clinic
565
mi
from
Houston, TX
Click here to add this to my saved trials
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients
Status: Enrolling
Updated:  12/11/2017
Thomas Jefferson University Hospital
1225
mi
from
Philadelphia, PA
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients
Status: Enrolling
Updated: 12/11/2017
Thomas Jefferson University Hospital
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Valley Medical Oncology Consultants - Castro Valley
1321
mi
from
Castro Valley, CA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Valley Medical Oncology Consultants - Castro Valley
1321
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
East Bay Radiation Oncology Center
1321
mi
from
Castro Valley, CA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
East Bay Radiation Oncology Center
1321
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Contra Costa Regional Medical Center
1321
mi
from
Martinez, CA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Contra Costa Regional Medical Center
1321
mi
from
Martinez, CA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Highland General Hospital
1328
mi
from
Oakland, CA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Highland General Hospital
1328
mi
from
Oakland, CA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Alta Bates Summit Medical Center - Summit Campus
1330
mi
from
Oakland, CA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Alta Bates Summit Medical Center - Summit Campus
1330
mi
from
Oakland, CA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Michiana Hematology-Oncology
685
mi
from
Elkhart, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Michiana Hematology-Oncology
685
mi
from
Elkhart, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Elkhart General Hospital
685
mi
from
Elkhart, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Elkhart General Hospital
685
mi
from
Elkhart, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Elkhart Clinic, LLC
685
mi
from
Elkhart, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Elkhart Clinic, LLC
685
mi
from
Elkhart, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Community Howard Regional Health
654
mi
from
Kokomo, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Community Howard Regional Health
654
mi
from
Kokomo, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Michiana Hematology Oncology
671
mi
from
South Bend, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Michiana Hematology Oncology
671
mi
from
South Bend, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Michiana Hematology Oncology
660
mi
from
Plymouth, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Michiana Hematology Oncology
660
mi
from
Plymouth, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Memorial Hospital of South Bend
671
mi
from
South Bend, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Memorial Hospital of South Bend
671
mi
from
South Bend, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Michiana Hematology Oncology-PC Westville
636
mi
from
Westville, IN
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Michiana Hematology Oncology-PC Westville
636
mi
from
Westville, IN
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Newton-Wellesley Hospital
1436
mi
from
Newton, MA
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Newton-Wellesley Hospital
1436
mi
from
Newton, MA
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Comprehensive Cancer Care, PC
404
mi
from
Saint Louis, MO
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Comprehensive Cancer Care, PC
404
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Nevada Cancer Research Foundation CCOP
960
mi
from
Las Vegas, NV
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Nevada Cancer Research Foundation CCOP
960
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
University Medical Center of Southern Nevada
962
mi
from
Las Vegas, NV
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
University Medical Center of Southern Nevada
962
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/11/2017
Memorial Hospital of Rhode Island
1425
mi
from
Pawtucket, RI
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/11/2017
Memorial Hospital of Rhode Island
1425
mi
from
Pawtucket, RI
Click here to add this to my saved trials